Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Breast cancer, metastatic

2194 - SToRM: a clinical cohort to identify genetic variability related to metastatic phenotypes


10 Sep 2017


Breast cancer, metastatic


David Cox


Annals of Oncology (2017) 28 (suppl_5): v605-v649. 10.1093/annonc/mdx440


D. Cox1, E. Blanc2, G. Romieu3, M. Rios4, C. Becuwe5, C. Jouannaud6, L. Chaigneau7, M. Arnedos8, H. Orfeuvre9, T. Petit10, N. Quenel Tueux11, J. Jacquin12, J. Ferrero13, S. Abadie Lacourtoisie14, F. Penault-Llorca15, C. Segura-Ferlay2, I. Moullet16, T. Bachelot17, X. Pivot18

Author affiliations

  • 1 Crcl, Centre Léon Bérard, 69008 - Lyon/FR
  • 2 Drci, Centre Léon Bérard, 69008 - Lyon/FR
  • 3 Oncology, ICM Regional Cancer Institute of Montpellier, 34298 - Montpellier/FR
  • 4 Oncology, Institut de Cancérologie de Lorraine - Alexis Vautrin, 54519 - Vandoeuvre les Nancy/FR
  • 5 Oncology, Centre d'Oncologie de Gentilly, 54100 - Nancy/FR
  • 6 Oncology, Institut Jean Godinot, 51056 - Reims/FR
  • 7 Oncology, CHU Besançon, Besancon/FR
  • 8 Oncology, Institut de cancérologie Gustave Roussy, Villejuif/FR
  • 9 Service Onco-hématologie, Hôpital Fleyriat, 01012 - BOURG-EN-BRESSE/FR
  • 10 Oncology, Centre Paul Strauss Centre de Lutte contre le Cancer, 67065 - Strasbourg/FR
  • 11 Oncology, Institute Bergonié, 33076 - Bordeaux/FR
  • 12 Oncology, Institut de Cancérologie Lucien Neuwirth, 4227 - Saint Priest en Jarez/FR
  • 13 Oncology, Centre Antoine Lacassagne, 6100 - Nice/FR
  • 14 Oncology, Centre Paul Papin, 49100 - Angers/FR
  • 15 Oncology, Centre Jean Perrin, 63011 - Clermont-Ferrand/FR
  • 16 Oncology, Clinique de la Sauvegarde, 69009 - Lyon/FR
  • 17 Medical Oncology, Centre Leon Berard, 69008 - Lyon/FR
  • 18 Oncology, CHU Besançon, Hôpital Jean Minjoz, 25030 - Besançon/FR


Abstract 2194


Advances in screening and treatment have reduced mortality from breast cancer. Once the disease progresses to metastasis, survival is limited. We have initiated the SToRM clinical cohort to study the contribution of the patient’s genetic background to clinically relevant phenotypes in metastasis.


1502 women were included in SToRM at metastatic progression from March 2012 to May 2014. A genome wide association study was carried out in 1250 patients, using the Illumina HumanCore Exome chip set. This chip set is composed of over 250,000 variants designed to capture common variation across the genome, as well as over 200,000 variants in coding regions. Patients are followed through contact with their clinical team to capture information regarding their treatment and survival. SToRM is designed to complement the SIGNAL/PHARE cohort of over 10,000 early breast cancer patients.


Delay between primary diagnosis and metastasis (average 58.5 months (±73.5)), and tumor type (luminal like (n = 747), HER2 + (n = 249), triple negative (n = 194), is available for SToRM patients. As of April 2017, 875 deaths are reported. As expected, survival probability is highly correlated with tumor type (p = 2.27x10−38), with triple negative patients showing median survival after metastatic diagnosis of less than 24 months, while median survival for luminal and HER2+ patients is longer than 36 months. Overall, no variants show associations with survival. There are, however, borderline associations between a number of variants and survival among triple negative and HER2+ patients. As of July 2017, median follow-up in SIGNAL is 3.8 years, and 7 years in PHARE, 1497 patients have progressed, and 154 deaths have been reported.


Genetic variants are important factors of risk for developing breast cancer. We have just begun to scratch the surface of the wealth of data that the SIGNAL/PHARE and SToRM clinical cohorts provide with respect to genetics and response to treatment and survival among breast cancer patients. Understanding how genetic variants influence outcomes may lead to better understanding of breast cancer in general. Furthermore, genetic variants associated with response to treatment may be used as stratification variables in future clinical trials.

Clinical trial identification

SToRM: NCT01460186, SIGNAL/PHARE: NCT00381901/RECF1098

Legal entity responsible for the study

SToRM: Centre Léon Bérard, SIGNAL/PHARE: INCa


Foundation Cancer de Sein-Parlons On!, INCa


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.